India Glycols logo

India Glycols

INDIAGLYCO NSE

Key Fundamentals

MicrocapBreweries & DistilleriesConsumer Goods
Market Cap
₹2,011 Cr
Volatility
High Risk
P/E Ratio
6.14
EBITDA
₹654 Cr
Return on Equity
9.98%
Debt to Equity
0.58
Book Value
₹437.55
52W High
₹1,222
52W Low
₹160.37

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

1
  • Stock is trading at 0.67 times its book value

Weaknesses

1
  • Company has a low return on equity of 10.4% over last 3 years.

Growth Rate

Revenue Growth
11.46% lower than 3Y
Net Income Growth
26.81% lower than 3Y
Cash Flow Change
112% higher than 3Y
ROE
-2.54% lower than 3Y
ROCE
1.86% lower than 3Y
EBITDA Margin (Avg.)
11.74% lower than 3Y

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 44d ago
AI opinion · based on fundamentals
Risk medium

India Glycols Ltd is a diversified green petrochemical and potable spirits company trading at a market cap of ₹7,678 Cr with a P/E of 25.9x. The company has delivered 17% compounded sales growth over 3 years and 39% compounded profit growth over the same period, though its return on equity remains modest at around 10-11%. Its debt-to-equity ratio stands near 0.86x and the stock trades at 2.58x book value.

Bull Case 8
  • Strong 3-year compounded profit growth of 39% indicates improving profitability and operating leverage across business segments
  • TTM revenue growth of 12% and 3-year compounded sales CAGR of 17% demonstrate consistent top-line momentum
  • Stock has delivered 54% CAGR over 3 years and 37% CAGR over 10 years, reflecting sustained long-term wealth creation
  • FY26 net profit surged 56.5% YoY to ₹282 Cr from ₹180 Cr in FY25, showing an acceleration in earnings trajectory
  • India's only integrated green petrochemical company using renewable agricultural feedstock, positioning it well for ESG-driven demand and ethanol-blending policies
  • Diversified revenue streams across Bio-Based Chemicals, Potable Spirits, and Biopharma segments reduce single-segment dependency
  • Dividend payout increased from 80% to 100% of face value in FY25, with total dividend outgo rising to ₹30.96 Cr from ₹24.77 Cr, signaling management confidence
  • 10-year compounded profit CAGR of 74% reflects a long runway of earnings expansion from a low base
Bear Case 8
  • Return on equity has averaged only 10% over 3, 5, and 10 years, indicating modest capital efficiency relative to the 25.9x P/E multiple
  • Stock trades at 2.58x book value, which is elevated for a company generating just 10-11% ROE, suggesting limited margin of safety
  • Debt-to-equity ratio near 0.86x implies meaningful financial leverage, increasing vulnerability to interest rate hikes or earnings slowdowns
  • Dividend yield of only 0.66% offers limited income support at current valuations
  • 5-year compounded profit growth of just 14% is significantly lower than the 3-year figure of 39%, indicating earnings volatility across cycles
  • 10-year compounded sales CAGR of only 6% suggests historically sluggish top-line growth before the recent acceleration
  • Commodity-linked business exposed to ethylene oxide and molasses price fluctuations, which can compress margins in adverse cycles
  • Q3FY25 revenue of ₹975 Cr came below analyst estimates, highlighting execution risk and demand uncertainty in certain quarters

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 42d ago
Positives 1
  • NCLT approves demerger scheme Jul 17

    NCLT Allahabad Bench sanctioned the demerger of India Glycols' Bio Pharma and Spirits undertakings on July 17, 2026, enabling the company to unlock value through separate focused entities.

Neutral 2
  • Director appointed at subsidiary Aug 1

    Akshay Bansal appointed as Additional Director and KMP at subsidiary Ennature Bio Pharma effective July 31, 2026, for a five-year term, addressing regulatory observations on the Scheme of Arrangement.

  • 42nd AGM scheduled Aug 19 Jul 22

    India Glycols will hold its 42nd AGM on August 19, 2026, via video conferencing to cover FY 2025-26 results.

TL;DR: India Glycols is progressing well on its corporate restructuring front with NCLT approval for the demerger of Bio Pharma and Spirits businesses, a move that should unlock standalone value. No visible headwinds in recent news flow. The management reshuffle at Ennature Bio Pharma signals preparation for post-demerger operations. The trend is constructive as the company moves toward a leaner, more focused structure.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
689
775
904
926
969
961
975
863
1,040
1,092
1,102
976
1,130
Expenses
589
679
802
822
843
845
852
717
891
935
927
810
961
Operating Profit
100
96
102
105
126
116
124
146
150
158
175
166
170
OPM %
15%
12%
11%
11%
13%
12%
13%
17%
14%
14%
16%
17%
15%
Other Income
12
12
9
10
14
15
19
13
20
14
3
14
21
Interest
28
29
31
33
36
40
44
45
45
49
47
26
25
Depreciation
21
28
26
26
28
28
27
33
34
38
41
41
42
PBT
64
50
54
56
76
63
71
82
91
84
91
112
123
Tax %
20%
24%
23%
24%
20%
22%
20%
22%
19%
22%
25%
23%
21%
Net Profit
51
38
42
42
60
50
57
64
73
65
68
87
97
EPS in Rs
8.25
6.13
6.71
6.81
9.74
8.02
9.16
10.33
11.81
10.51
10.09
12.97
14.45
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
2,579
2,324
2,500
3,034
3,357
2,735
2,317
2,868
2,651
3,294
3,768
4,211
4,301
Expenses
2,455
2,149
2,263
2,712
2,941
2,433
2,026
2,599
2,346
2,879
3,257
3,562
3,632
Operating Profit
124
175
237
322
416
303
291
269
305
415
511
649
669
OPM %
4.8%
8%
9%
11%
12%
11%
13%
9%
12%
13%
14%
15%
16%
Other Income
-16
-47
7
23
17
24
15
260
54
30
61
50
51
Interest
163
139
127
125
143
97
83
70
100
121
164
167
148
Depreciation
89
69
72
73
76
78
80
80
94
101
115
155
163
PBT
-144
-81
45
147
213
153
143
379
165
223
292
377
410
Tax %
-38%
-30%
22%
34%
38%
25%
8%
10%
15%
23%
21%
22%
—
Net Profit
-89
-57
35
97
133
115
132
340
141
173
231
293
316
EPS in Rs
-14.3
-9.16
5.65
15.57
21.39
18.49
21.23
54.81
20.17
27.9
37.25
43.7
48.02
Div. Payout %
0%
0%
9%
13%
14%
16%
14%
7%
19%
14%
13%
17%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
31
31
31
31
31
31
31
31
31
31
31
34
Reserves
266
687
721
814
932
1,003
1,138
1,761
1,870
2,020
2,225
2,899
Borrowings
2,264
1,236
1,095
834
1,000
999
1,137
1,047
1,112
1,348
1,892
1,691
Other Liabilities
593
1,665
1,645
1,742
1,821
2,053
1,814
1,792
1,845
2,218
2,029
1,900
Total Liabilities
3,154
3,620
3,492
3,421
3,784
4,086
4,119
4,631
4,858
5,617
6,176
6,523
Fixed Assets
1,146
2,029
2,111
2,156
2,173
2,228
2,193
2,318
2,717
3,205
3,829
4,554
CWIP
162
181
91
89
137
172
126
243
125
84
98
37
Investments
4
28
25
24
21
26
27
336
318
335
381
389
Other Assets
1,843
1,382
1,265
1,152
1,453
1,660
1,774
1,734
1,698
1,993
1,867
1,543
Total Assets
3,154
3,620
3,492
3,421
3,784
4,086
4,119
4,631
4,858
5,617
6,176
6,523
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
-171
1,231
302
502
147
343
137
116
326
439
362
769
Investing
175
-78
-40
-103
-128
-151
-148
76
-330
-503
-736
-767
Financing
-4
-1,168
-263
-399
3
-216
11
-189
-1
90
354
23
Net Cash Flow
0
-15
-1
0
22
-23
0
4
-5
25
-20
25
Free Cash Flow
-53
1,137
260
373
9
193
-11
-264
-109
-103
-391
-47
CFO/OP
-136
705
127
156
37
127
53
51
123
108
75
122
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
62
57
57
40
35
76
57
51
59
43
35
30
Inventory Days
109
128
129
87
124
146
166
148
209
224
209
139
Days Payable
55
120
144
152
143
155
158
137
209
222
175
123
Cash Conversion Cycle
115
66
42
-25
17
67
65
62
60
44
70
47
Working Capital Days
-110
-94
-117
-78
-50
-64
-79
-31
-46
-63
-56
-49
ROCE %
3%
5%
9%
15%
20%
14%
10%
9%
8%
11%
12%
12%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view India Glycols insights

62 extracted metrics + investor summaries across FY09–FY26.

Log in — free

Shareholding Pattern

FIIs2.24%Promot.59.63%DIIs5.22%Others6.76%Public26.15%As ofJun 2026

Documents

Frequently Asked Questions about India Glycols

What does India Glycols Ltd do?
Established in 1988, India Glycols Ltd. is engaged in the manufacturing of green technology-based bulk, specialty & performance chemicals, and natural gums, spirits, industrial gases, sugar, and nutraceuticals. [1][2]
Where is India Glycols Ltd (INDIAGLYCO) listed?
India Glycols Ltd trades as INDIAGLYCO on the NSE and under code 500201 on the BSE.
Which sector does India Glycols Ltd belong to?
India Glycols Ltd is classified under the Consumer Goods sector, in the Breweries & Distilleries industry.
What is the market capitalisation of India Glycols Ltd?
India Glycols Ltd has a market capitalisation of ₹2,011 Cr, which places it in the Small Cap band.
What is the PE ratio of India Glycols Ltd?
India Glycols Ltd trades at a PE ratio of 6.14, against a book value of ₹437.55 per share.
What is the 52-week high and low of India Glycols Ltd?
Over the last 52 weeks India Glycols Ltd has traded between ₹160.37 and ₹1,222.
Does India Glycols Ltd pay dividends?
India Glycols Ltd has a dividend yield of 2.42%.
What is the Return on Equity (ROE) of India Glycols Ltd?
India Glycols Ltd reported a return on equity of 9.98%. Its debt-to-equity ratio is 0.58.

Company Information

Established in 1988, India Glycols Ltd. is engaged in the manufacturing of green technology-based bulk, specialty & performance chemicals, and natural gums, spirits, industrial gases, sugar, and nutraceuticals. [1][2]

Website indiaglycols.com
CEO Mr. Uma Shankar Bhartia
Employees 1,357
Listed 2005-07-01
Face Value ₹ 5
Issued Size 6,70,26,765

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/INDIAGLYCO.md for India Glycols Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Consumer Goods → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List